louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02769416: The National Center for Testing Treatments in Chronic Spinal Cord and Traumatic Brain Injury
Official title: The National Center for Testing Treatments in Chronic Spinal Cord and Traumatic Brain Injury
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Spinal Cord Injury
Traumatic Brain Injury
Keywords: spinal cord injury
traumatic brain injury
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
First posted: 2016-05-11
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Chronic spinal cord and traumatic brain injury patients, family members, and healthy vounteers

Brief summary: The NCTT is a prospective, multicenter, observational research network for subjects with chronic spinal cord and/or chronic traumatic brain injury.

Detailed description: Current treatment for Spinal Cord Injury and Traumatic Brain Injury focuses on stabilizing the patient and preventing secondary injury with the aim of maximizing the best chance of recovery. Most patients will show varying amounts of recovery, but, when the injury is severe, that recovery is only partial. Enrollment in the NCTT will allow for classification and characterization of injury, function, co-morbidities, secondary issues/problems, research interests and will serve as a conduit for enrollment into interventional studies.

Eligibility criteria: Inclusion Criteria:

* History of spinal cord injury and/or brain injury
* Able to provide HIPAA authorization to share prior medical records/imaging
* Age 18 and older.

Exclusion Criteria:

* Life expectancy less than 6 months, vegetative state or co-existing disease or other characteristic that precludes appropriate diagnosis of spinal cord or brain injury.
* Other condition that, in the opinion of the site investigator, would interfere with adherence to study requirements.
* Inability or unwillingness of subject or legal guardian/representative to give informed consent (e.g., ward of the state).

Primary outcomes:
measure: International Standard Neurological Classification of Spinal Cord Injury
timeFrame: greater than 6 months post-injury
measure: Disability Rating Scale
timeFrame: greater than 6 months post-injury
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: UTHealth
name: Georgene Hergenroeder, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04858516: Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer
Official title: Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in ER-positive, HER2-positive Breast Cancer (neoPEHP): an Exploratory, Open-label, Multi-center Phase 2 Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
Lead sponsor: Guangdong Provincial People's Hospital
Sponsor class: OTHER
First posted: 2021-04-26
Enrollment: 57
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: neoPEHP is a multicohort, open-label, exploratory, phase 2 study. Patients were eligible if they had previously untreated, histologically confirmed, unilateral, invasive, HER2-positive, ER-positive breast cancer and were suitable for neoadjuvant therapy. Patients were treated every 3 weeks with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and oral pyrotinib (400 mg po QD) for six cycles plus oral palbociclib (125 mg once a day for 21 days in a 4-week cycle) and oral exemestane (25 mg po QD) every 4 weeks for 24 weeks. The primary endpoints was pathological complete response.


Eligibility criteria: Inclusion Criteria:

* We judged patients eligible for the first study cohort if they had previously untreated, histologically confirmed, unilateral, invasive, HER2-positive (3+ on immunohistochemistry or neu-amplified) and ER-positive (\>10% of cells in the tumour expressing ER) breast cancer. Other inclusion criteria were age 18 years or older, Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less, and tumour classified between cT1c and cT4a-d.

Exclusion Criteria:

* metastatic disease, bilateral breast cancer, other malignant disease, inadequate bone marrow or renal function, impaired liver function, impaired cardiac function, uncontrolled hypertension, pregnancy, and refusal to use contraception.

Primary outcomes:
measure: pathological complete response(ypT0/is,ypN0, pCR)
timeFrame: 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02501616: Effect of Dapagliflozine on Systemic and Renal Endothelial Function
Official title: Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor on Systemic and Renal Endothelial Function in Patients With Type 2 Diabetes Mellitus Without History of Coronary Artery Disease (SOCCER Trial)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Endothelial Function
Type 2 Diabetes
Keywords: SGLT2 inhibitor
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2015-07-17
Enrollment: 22
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a phase 4, single center, randomized, open-labeled, cross-over design study. The primary objective of the study is to compare effect of dapagliflozine and metformin on endothelial function.

Subjects are randomized to initial metformin or initial dapagliflozin group and maintained initial treatment for 8 weeks. During that period, dose of dapagliflozin is maintained 10mg/day and metformin can be titrated upto 2000 mg/day. After 1 weeks of washout period, 8 weeks' cross-over is followed.


Eligibility criteria: Inclusion Criteria:

1. Present with type 2 diabetes based on the disease diagnostic criteria as described by the World Health Organization (WHO)
2. Treated with diet and exercise alone for recent 3 months
3. Aged 20-80 years
4. HbA1c 7\~9%
5. This inclusion criterion applies to females of childbearing potential (not surgically sterilized and between menarche and 1-year postmenopause) only.

   * Are not breastfeeding.
   * Test negative for pregnancy at the time of screening based on a blood serum pregnancy test.
   * Intend not to become pregnant during the study.

Exclusion Criteria:

1. Previous history of IHD or brain infarct
2. Having typical anginal pain or atypical chest pain with dyspnea
3. Modification of Diet in Renal Disease (MDRD) estimated GFR≥60 mL/min

Primary outcomes:
measure: Reactive hyperemic index to measure endothelial function
timeFrame: 8 weeks
Secondary outcomes:
measure: N-acetyl-β-D-glucosaminidase as a measure of renal tubular injury
timeFrame: 8 week
measure: Urine albumin excretion ratio
timeFrame: 8 week
measure: Urine β2 microglobulin
timeFrame: 8 week
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Boramae medical center
Study officials:
affiliation: Boramae medical center, 20 Boramae-ro 5-gil,Dongjak-Gu,Seoul 156-707, Korea
name: Min Kyong Moon, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03034616: Ovarian Laparoscopic In Vivo Activation of Ovary for Premature Ovarian Insufficiency
Official title: in Vivo Activation of Ovarian Cortex in Premature Ovarian Insufficiency
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Primary Ovarian Insufficiency
Keywords: Primary ovarian insufficiency
In-vivo activation
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2017-01-27
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The OLIVA device will enable to perform shallow slashes on the ovarian cortex in patients undergoing oophorectomy. Prior to the resection of the ovary from the pedicle we will perform 5 parallel slashes 3 cm long. following oophorectomy investigation by the pathologist as to the depth of cuts and proximity to blood vessels and later.

Detailed description: The OLIVA device is built of 5 parallel razor blades enclosed by protective cap

Eligibility criteria: Inclusion Criteria:

* Peri/menopausal women undergoing laparoscopic oophorectomy

Exclusion Criteria:

* Women with ovarian malignancy
* Women with polycystic ovarian syndrome

Primary outcomes:
measure: Depth of cuts and closeness to blood vessel
timeFrame: Up to 30 days after procedure
Secondary outcomes:
measure: Proximity of cuts to blood vessel
timeFrame: Up to 30 days after procedure
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02942316: Pupillary Dilation Reflex (PDR) Evaluation During General Anesthesia
Official title: Pupillary Dilation Reflex (PDR) Evaluation During General Anesthesia: a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain
Keywords: Heart Rate
Reflex, Pupillary
Monitoring, Intraoperative
Lead sponsor: University Hospital, Antwerp
Sponsor class: OTHER
First posted: 2016-10-24
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: In this study, the pupillary dilation reflex is measured as a nociceptive indicator during elective abdominal surgery under general anesthesia.

Detailed description: An infrared camera of the video pupillometer measures the pupillary dilation reflex (PDR) in response of a nociceptive stimulus. This autonomic reflex, parasympathetic mediated in sedated patients, can be generated by various pain stimuli (built in standardized protocol, surgical incision, ...) The PDR is a robust reflex, even in patients under general anesthesia, and provides a potential evaluation of the autonomous circuit within the nociceptive evaluation based on pupil dilation upon A-delta and C fibers in both electrical or mechanic stimulation. This mono-centric project involving American Society of Anesthesiologists (ASA) classification I-II patients undergoing elective abdominal surgery under general anesthesia are recruited. Enrolled patients perioperative undergo PDR measurements at four different standardized times.

Eligibility criteria: Inclusion Criteria:

* Scheduled abdominal surgery
* ASA I-II

Exclusion Criteria:

* History of eye deformity, invasive ophthalmologic surgery, impaired pupil reflex in advance
* Kown cranial nerve(s) deficit
* Infection of the eye
* Predicted difficult airway management (DAF Guidelines)
* Chronic opioid use (\>3 months)
* Ongoing treatment with beta-blockers, dopamine antagonists, topical atropine

Primary outcomes:
measure: Pupillary Reflex Dilation
timeFrame: Perioperative phase
Secondary outcomes:
measure: Patient Movement
timeFrame: Perioperative phase
measure: Vital signs
timeFrame: Perioperative phase
Other outcomes:
Locations:
city: Edegem
country: Belgium
facility: University hospital Antwerp
state: Antwerp
Study officials:
affiliation: University Hospital, Antwerp
name: Robert Slappendel, MD, PhD
role: STUDY_DIRECTOR
affiliation: University Hospital, Antwerp
name: Michiel Baeten, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital, Antwerp
name: Davina Wildemeersch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03063216: Shanghai Pediatric Cataract Study
Official title: Visual Outcome Evaluation and Genetic Analysis: Shanghai Pediatric Cataract Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pediatric Cataract
Congenital Cataract
Traumatic Cataract
Visual Outcome
Genetic Anticipation
Lead sponsor: Evidence Based Cataract Study Group
Sponsor class: OTHER
Collaborators: name: Eye & ENT Hospital of Fudan University
First posted: 2017-02-24
Enrollment: 10000
Sex: ALL
Minimum age (years): 2
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Medical centre: Eye and ENT Hospital of Fudan University

Brief summary: The purpose of this study is to evaluate the long-term visual outcome of the cataract surgery using a large-scale and comprehensive database of pediatric cataract participants, including congenital and traumatic cataract. The investigators will further investigate into the various genetic and environmental factors that may contribute to the pathogenesis of pediatric cataract.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of pediatric cataract
* Must be able to cooperate with the ophthalmic examination

Exclusion Criteria:

* Clinical diagnosis of mental illness
* Mentally disabled

Primary outcomes:
measure: Differences in the visual outcomes of pediatric cataract patients.
timeFrame: Follow-up until ten years after surgery.
measure: Genetic diversity based on biospecimen samples of pediatric cataract patients.
timeFrame: Analyzed within six months after surgery.
Secondary outcomes:
measure: Differences in the clinical phenotypes of pediatric cataract patients.
timeFrame: Evaluated before receiving the cataract surgery.
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Eye and ENT Hospital of Fudan University
state: Shanghai
Study officials:
affiliation: Eye and ENT Hospital of Fudan University
name: Yi Lu, M.D.
role: STUDY_CHAIR
affiliation: Eye and ENT Hospital of Fudan University
name: Xiangjia Zhu, M.D.
role: STUDY_DIRECTOR
affiliation: Eye and ENT Hospital of Fudan University
name: Keke Zhang, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Eye and ENT Hospital of Fudan University
name: Wenwen He, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Eye and ENT Hospital of Fudan University
name: Yu Du, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Eye and ENT Hospital of Fudan University
name: Yinglei Zhang, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Eye and ENT Hospital of Fudan University
name: Ruiqi Chang, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Zhu X, He W, Du Y, Kraus CL, Xu Q, Sun T, Yu J, Lu Y. Presence of Posterior Staphyloma in Congenital Cataract Children. Curr Eye Res. 2019 Dec;44(12):1319-1324. doi: 10.1080/02713683.2019.1637437. Epub 2019 Jul 5.
Clinical trial NCT06074016: Pharmacokinetics in Oral and Intranasal Formulations of Zolmitriptan.
Official title: Pharmacokinetic Model Based on Population Physiology of Oral and Intranasal Formulations of Zolmitriptan in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Parc de Salut Mar
Sponsor class: OTHER
Collaborators: name: Food and Drug Administration (FDA)
First posted: 2023-10-10
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This is a phase I study to evaluate the PBPK of zolmitriptan intranasal versus oral administration.


Eligibility criteria: Inclusion Criteria:

* Healthy male or female volunteers by physical examination, vital signs, ECG, and safety laboratory parameters and results must be within normal ranges or considered not clinically relevant by the investigator.
* Age ≥ 18 years and ≤ 55 years.
* Body mass index (BMI) ≥ 18 and ≤ 30.
* Able/willing to accept restrictions regarding diet, physical exercise, and consumption of alcohol and/or xanthine-containing items when outside the Clinical Research Unit (CRU)
* Able to read Spanish and adhere to study requirements.
* Informed consent signed before any procedure required by the study.

Exclusion Criteria:

* Smoking.
* History or clinically relevant diseases.
* Be under administrative or legal supervision.
* Pregnancy and breastfeeding.
* Positive blood or urine drug of abuse test or breathalyzer prior to study drug administration.
* Any history, disease, disorder, condition, anomaly or clinical finding that is relevant in the judgment of the investigator that may interfere with the study.
* Known hypersensitivity to any drug or excipient of the drug.
* Use of medications, inhibitors, any prescription or over-the-counter products, including herbs, homeopathy, vitamins, minerals, and nutritional supplements, before or during the study, that may interfere with the conduct and results of the study.
* Donation or transfusion of blood or plasma before, during or after study drug administration.
* History of inadequate venous access and/or experience of difficulty donating blood.
* Not being able/unwilling to accept restrictions regarding diet, physical exercise and consumption of alcohol and/or articles containing xanthine when outside the CRU.
* Subject included in a clinical study in the 3 months prior to the study drug administration.

Primary outcomes:
measure: Effects of zolmitriptan on heart rate (HR).
timeFrame: Up to 24 hours.
measure: Effects of zolmitriptan on systolic and diastolic blood pressure (BP).
timeFrame: Up to 24 hours.
Secondary outcomes:
measure: Concentration of zolmitriptan on vasoactive intestinal polypeptide (VIP) in captures Day 1.
timeFrame: Up to 24 hours.
Other outcomes:
measure: Adverse effects.
timeFrame: Up to 24 hours.
Locations:
city: Barcelona
country: Spain
facility: IMIM (Hospital del Mar Medical Research Institute)
Study officials:
References:
Clinical trial NCT00002216: A Comparison of Two Multi-Drug Therapies in HIV-Infected Patients Who Have Never Received Anti-HIV Treatment
Official title: A Comparison of a Four-Drug Regimen Comprised of 141W94, 1592U89, and Combivir With a Three-Drug Regimen Comprised of Nelfinavir and Combivir in Antiretroviral-Naive HIV-Infected Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Keywords: Drug Therapy, Combination
HIV Protease Inhibitors
VX 478
Reverse Transcriptase Inhibitors
Anti-HIV Agents
abacavir
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare 2 combination drug therapies in HIV-infected patients who have never received anti-HIV treatment.

Detailed description: In this open-label study antiretroviral-naive patients are randomized to one of two drug regimens:

Arm I: 141W94 (amprenavir), 1592U89 (abacavir), and Combivir (3TC/AZT tablet). Arm II: Nelfinavir and Combivir.

Eligibility criteria: Inclusion Criteria

Patients must have:

* CD4 count \> 50.
* HIV RNA \> 5,000.
* No active AIDS (excluding CD4 count \< 200).
* Ability to comply with dosing schedule and protocol evaluations.

Prior Medication:

Allowed:

* 3TC or any protease inhibitor, if \< 1 week of therapy.
* Other nucleoside analogs, if \< 4 weeks of therapy.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms or conditions are excluded:

* Active AIDS (not including CD4 count \< 200).
* Malabsorption syndrome affecting drug absorption.

Concurrent Medication:

Excluded:

Enrollment in any other investigational drug protocol.

Prior Medication:

Excluded:

Non-nucleoside reverse transcriptase inhibitors.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: Anderson Clinical Research
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01898624: Specified Drug Use-results Survey of Betanis Tablets
Official title: Specified Drug Use-results Survey of Betanis Tablets in OAB Patients With Coexisting Glaucoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Overactive Bladder
Keywords: mirabegron
Overactive Bladder
Betanis®
glaucoma
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2013-07-12
Enrollment: 300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: OAB patients with coexisting glaucoma treated with mirabegron

Brief summary: To investigate the effects of mirabegron on the symptoms of glaucoma in overactive bladder (OAB) patients with coexisting glaucoma.


Eligibility criteria: Inclusion Criteria:

* diagnosed as OAB and treated with mirabegron
* diagnosed as glaucoma (including normal tension glaucoma)
* having intraocular pressure measurement conducted more than twice within six months before the start of the mirabegron treatment

Primary outcomes:
measure: The occurrence of ocular adverse events such as increased intraocular pressure and worsening of glaucoma
timeFrame: 12 weeks
Secondary outcomes:
measure: Changes in OABSS (Over Active Bladder Symptoms Score)
timeFrame: Baseline and 12 weeks of treatment
Other outcomes:
Locations:
city: Chubu
country: Japan
city: Chugoku
country: Japan
city: Kansai
country: Japan
city: Kanto
country: Japan
city: Kyushu
country: Japan
city: Shikoku
country: Japan
city: Tohoku
country: Japan
Study officials:
affiliation: Astellas Pharma Inc
name: Central Contact
role: STUDY_DIRECTOR
References:
Clinical trial NCT04857424: Quality of Life Assessment Between Internal Endoscopic Versus Percutaneous Drainage in Biliary Obstruction
Official title: A Comparative Quality of Life Assessment Between Internal Endoscopic Versus Percutaneous Drainage of Benign and Malignant Biliary Obstruction
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Biliary Obstruction
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-04-23
Enrollment: 206
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients aged 18 or over with a diagnosis of benign or malignant biliary obstruction who have underwent an ERCP and/or PTBD will be identified through Best Practices Advisory (BPA), referrals from the clinics of GI consultants and the gastroenterology department procedure schedules at Mayo Clinic, Rochester.

Brief summary: The aim of this study is to compare the quality of life in subjects with benign and malignant biliary obstruction who have or will undergo endoscopic retrograde cholangiopancreatography (ERCP) and/or percutaneous trans-hepatic biliary drainage (PTBD).


Eligibility criteria: Inclusion Criteria:

* Patients with benign biliary obstruction
* Patients with malignant biliary obstruction
* Patients undergoing ERCP and/or PTBD

Exclusion Criteria:

* Patients with gallstone disease
* Patients who will undergo ERCP who have previously underwent a PTBD
* Patients who will undergo PTBD who have previously underwent an ERCP
* Female patients who are pregnant
* Prisoners and other vulnerable populations

Primary outcomes:
measure: Change in European Quality of Life-5 Dimensions questionnaire score
timeFrame: Baseline, 1 month, 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Andrew Storm, MD
role: PRINCIPAL_INVESTIGATOR
References: